Thrombosis and Coagulopathy in COVID-19

• Published in: Current problems in cardiology Vol. 46; no. 3; p. 100742
• Main Authors: Gómez-Mesa, Juan Esteban, Galindo-Coral, Stephania, Montes, Maria Claudia, Muñoz Martin, Andrés J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2021; Mosby-Year Book
• Subjects: Blood Coagulation Disorders - epidemiology; Blood Coagulation Disorders - etiology; COVID-19 - complications; COVID-19 - epidemiology; Global Health; Humans; Incidence; Pandemics; SARS-CoV-2; Thrombosis - epidemiology; Thrombosis - etiology
• ISSN: 0146-2806; 1535-6280; 1535-6280
• DOI: 10.1016/j.cpcardiol.2020.100742

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.